Maze Therapeutics (NASDAQ:MAZE) CMO Harold Bernstein Sells 9,705 Shares of Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CMO Harold Bernstein sold 9,705 shares of the stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $26.22, for a total transaction of $254,465.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Harold Bernstein also recently made the following trade(s):

• On Thursday, September 3rd, Harold Bernstein sold 5,189 shares of Maze Therapeutics stock. The stock was sold at an average price of $26.01, for a total transaction of $134,965.89.
• On Wednesday, September 2nd, Harold Bernstein sold 5,106 shares of Maze Therapeutics stock. The stock was sold at an average price of $26.47, for a total value of $135,155.82.
• On Tuesday, September 1st, Harold Bernstein sold 16,141 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.36, for a total value of $425,476.76.
• On Thursday, August 13th, Harold Bernstein sold 16,142 shares of Maze Therapeutics stock. The shares were sold at an average price of $27.61, for a total value of $445,680.62.
• On Wednesday, July 1st, Harold Bernstein sold 14,609 shares of Maze Therapeutics stock. The stock was sold at an average price of $29.90, for a total value of $436,809.10.

Maze Therapeutics Trading Up 0.6%

Maze Therapeutics stock opened at $26.37 on Wednesday. Maze Therapeutics, Inc. has a 1 year low of $14.75 and a 1 year high of $53.65. The firm’s 50 day moving average price is $28.57 and its 200-day moving average price is $30.78. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.31 and a quick ratio of 18.31. The stock has a market cap of $1.46 billion, a P/E ratio of -10.46 and a beta of 2.17.

Maze Therapeutics (NASDAQ:MAZE) last posted its earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, meeting the consensus estimate of ($0.76). On average, equities analysts predict that Maze Therapeutics, Inc. will post -2.72 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently commented on MAZE. Wall Street Zen downgraded Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Maze Therapeutics in a report on Wednesday, June 24th. TD Cowen upgraded Maze Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. Finally, BTIG Research reissued a “buy” rating and issued a $46.00 price objective on shares of Maze Therapeutics in a research report on Wednesday, August 12th. Three equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Maze Therapeutics currently has an average rating of “Buy” and an average target price of $66.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. TRV GP IV LLC bought a new position in shares of Maze Therapeutics in the 2nd quarter worth $133,502,907. ARCH Venture Management LLC bought a new stake in Maze Therapeutics during the second quarter valued at about $122,983,582. BlackRock Inc. purchased a new position in Maze Therapeutics in the second quarter valued at about $104,525,000. Jupiter Topco LLC purchased a new position in Maze Therapeutics in the second quarter valued at about $101,764,000. Finally, Janus Henderson Group PLC raised its holdings in Maze Therapeutics by 318.0% in the fourth quarter. Janus Henderson Group PLC now owns 3,142,587 shares of the company’s stock worth $130,197,000 after purchasing an additional 2,390,713 shares in the last quarter.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.